Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14418568 | 0.83 | CNR1 (0.44) | CYP1A2CYP2A6NPC1RAB9AALDH1A1 | |
| SCHEMBL347592 | 0.80 | CYP2A6 (0.80) | CYP1A2CYP2A6TRPA1AKR1C3AKR1C2 | |
| SCHEMBL29407167 | 0.80 | CYP2A6 (0.80) | CYP1A2CYP2A6TRPA1AKR1C3AKR1C2 | |
| SCHEMBL14493551 | 0.79 | SKP2 (0.46) | CYP1A2NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL14493552 | 0.78 | TLR8 (0.46) | ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL29475635 | 0.78 | CYP2A6 (0.76) | CYP1A2CYP2A6TRPA1AKR1C3AKR1C2 | |
| SCHEMBL1878783 | 0.78 | CYP2A6 (0.76) | CYP1A2CYP2A6TRPA1AKR1C3AKR1C2 | |
| SCHEMBL14493613 | 0.77 | IDO1 (0.41) | CYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL22315164 | 0.77 | ALDH1A1 (0.33) | CYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL29076155 | 0.77 | CYP1A2 (0.61) | CYP1A2CYP2A6TRPA1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11638706-B2 | Methods for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
| EP-3892618-A1 | 4-PYRIDINYL FORMAMIDE COMPOUND OR DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | Qingdao KingAgroot Chemical Compound Co., Ltd. (CN) | 2021-10-13 | — | — | EP | disclosed |
| US-20210275526-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2021-09-09 | — | — | US | disclosed |
| US-11091462-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2021-08-17 | — | — | US | disclosed |
| US-10874672-B2 | Methods for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200377473-A9 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2020-12-03 | — | — | US | disclosed |
| US-20200370043-A1 | METHODS FOR MODIFYING RNA SPLICING | PTC THERAPEUTICS, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| US-20190000844-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2019-01-03 | — | — | US | disclosed |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-05 | — | — | US | disclosed |
| US-9675697-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-06-13 | — | — | US | disclosed |
| US-7229753-B2 | Photothermographic material and method for forming images | FUJIFILM CORPORATION (JP) | 2007-06-12 | — | — | US | disclosed |
| US-7229753-B2 | Photothermographic material and method for forming images | FUJIFILM CORPORATION (JP) | 2007-06-12 | — | — | US | disclosed |
| US-7223531-B2 | Photothermographic material | FUJIFILM CORPORATION (JP) | 2007-05-29 | — | — | US | disclosed |
| US-7223531-B2 | Photothermographic material | FUJIFILM CORPORATION (JP) | 2007-05-29 | — | — | US | disclosed |
| US-7208264-B2 | Photothermographic material and method of forming images | FUJIFILM CORPORATION (JP) | 2007-04-24 | — | — | US | disclosed |
| US-7208264-B2 | Photothermographic material and method of forming images | FUJIFILM CORPORATION (JP) | 2007-04-24 | — | — | US | disclosed |
| US-20070003882-A9 | Photothermographic material, and image forming method using same | FUKUI KOUTA | 2007-01-04 | — | — | US | disclosed |
| US-20070003882-A9 | Photothermographic material, and image forming method using same | FUKUI KOUTA | 2007-01-04 | — | — | US | disclosed |
| US-20070003884-A1 | Photothermographic material | FUJI PHOTO FILM CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| US-20070003884-A1 | Photothermographic material | FUJI PHOTO FILM CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210275526-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, FH | CYP1A2 2524/4885CYP2A6 2557/4885TRPA1 4396/4885 |
| US-11091462-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | MAP2K2, MAP2K5, MAP2K4 | CYP1A2 1312/4885CYP2A6 1247/4885TRPA1 1736/4885 |
| US-20190000844-A1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, FH | CYP1A2 2524/4885CYP2A6 2557/4885TRPA1 4396/4885 |
| US-20200370043-A1 | METHODS FOR MODIFYING RNA SPLICING | RBM17, SNRPE, SNRPA1 | CYP1A2 2720/4885CYP2A6 2870/4885TRPA1 4451/4885 |
| US-20200377473-A9 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | MAP2K2, MAP2K4, MAP2K5 | CYP1A2 1296/4885CYP2A6 1251/4885TRPA1 1682/4885 |
| US-10874672-B2 | Methods for treating Huntington's disease | HTT, HYPK, FH | CYP1A2 2524/4885CYP2A6 2557/4885TRPA1 4396/4885 |
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | CYP1A2 4793/4885CYP2A6 4772/4885TRPA1 4883/4885 |
| US-11638706-B2 | Methods for treating Huntington's disease | HTT, HYPK, FH | CYP1A2 2524/4885CYP2A6 2557/4885TRPA1 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.